Form 4: Akari Therapeutics Director Boosts Stake via Warrants

Akari Therapeutics Director Robert Bazemore acquired significant warrants and pre-funded warrants through a private placement and a debt-to-equity exchange, pending shareholder approval.

Summary

• Robert B. Bazemore, a Director of Akari Therapeutics Plc (AKTX), reported the acquisition of derivative securities on December 16, 2025.
• The acquisitions were made through two distinct transactions: a private placement and a note cancellation and exchange agreement.
• In the private placement, Bazemore acquired 123,731 unregistered pre-funded warrants (PIPE PFWs) and 123,731 accompanying Series G Warrants to purchase American Depositary Shares (ADSs).
• The combined purchase price for each PIPE PFW and Series G Warrant in the private placement was $0.4041.
• The Series G Warrants have an exercise price of $0.3883 per ADS, and the PIPE PFWs have an exercise price of $0.00001 per ADS.
• Through the note cancellation and exchange, Bazemore received 30,932 unregistered pre-funded warrants (Note Exchange Unregistered Pre-Funded Warrants) and 30,932 unregistered warrants (Note Exchange Unregistered Warrants) in exchange for an outstanding unsecured promissory note.
• The Note Exchange Unregistered Warrants have an exercise price of $0.3883 per ADS, and the Note Exchange Unregistered Pre-Funded Warrants have an exercise price of $0.00001 per ADS.
• Each ADS represents 2,000 Ordinary Shares of Akari Therapeutics Plc.
• Exercisability of all acquired warrants and pre-funded warrants is contingent upon shareholder approval.
• The Series G Warrants and Note Exchange Unregistered Warrants have a five-year term from shareholder approval, while the pre-funded warrants remain exercisable until fully exercised.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. A director increasing their stake signals confidence, and debt restructuring is generally favorable. However, the potential for future dilution from warrant exercise and the contingency of shareholder approval introduce some uncertainty.

Positives

• A Director increasing their beneficial ownership through warrant acquisitions can signal confidence in the company's future prospects.
• The note cancellation and exchange agreement reduces the company's outstanding debt, improving its balance sheet structure.

Negatives

• The issuance of warrants and pre-funded warrants, if exercised, will lead to dilution for existing shareholders.
• The exercisability of these securities is subject to shareholder approval, introducing an element of uncertainty.

Risks

• Shareholder approval is required for the warrants and pre-funded warrants to become exercisable, and there is a risk that this approval may not be obtained.
• Future exercise of these warrants and pre-funded warrants will result in dilution of existing shareholders' equity.
• The private placement and debt-to-warrant conversion could be perceived negatively by the market if not fully understood or if the terms are seen as unfavorable to existing shareholders.

Future Outlook

The exercisability of all acquired warrants and pre-funded warrants is contingent upon obtaining shareholder approval. The Series G Warrants and Note Exchange Unregistered Warrants will have a five-year term from the date of such approval, while the pre-funded warrants will remain exercisable until fully exercised.

Industry Context

Private placements and debt-to-equity (or debt-to-warrant) conversions are common financing strategies for biotechnology companies like Akari Therapeutics, particularly those in development stages, to raise capital or restructure debt without immediate public market offerings. Such transactions can reflect a company's need for capital or a strategic move to strengthen its balance sheet, often involving existing investors or directors.

Corporate Governance

Related Party Transactions

• The note cancellation and exchange agreement involved the Issuer and Robert Bazemore, a Director, converting an unsecured promissory note held by the Director into warrants and pre-funded warrants. This constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential future dilution upon exercise of warrants and pre-funded warrants, but also a signal of insider confidence. Shareholder approval is required for exercisability.
• Creditors (specifically Robert Bazemore): His unsecured promissory note was converted into derivative securities, changing his position from a creditor to a potential equity holder.

Next Steps

• Obtain shareholder approval for the exercisability of the acquired warrants and pre-funded warrants.

Key Dates

Keywords

Akari Therapeutics, AKTX, Form 4, Insider Transaction, Warrants, Pre-Funded Warrants, Private Placement, Debt Exchange, Beneficial Ownership, Director